ADMA BIOLOGICS, INC. (NASDAQ:ADMA) Files An 8-K Results of Operations and Financial Condition
On January 9, 2020, ADMA Biologics, Inc. issued a press release announcing its preliminary financial results for the three months and year ended December 31, 2019 and provided an update on its recent achievements and upcoming milestones. A copy of the press release is furnished herewith as Exhibit 99.1.*
|99.1||ADMA Biologics, Inc. Press Release, dated January 9, 2020.|
* The information in Item 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
ADMA BIOLOGICS, INC. Exhibit
EX-99.1 2 e619273_ex99-1.htm Exhibit 99.1 ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2019 Revenues and Provides 2020 Strategic Outlook Achieved Fourth Quarter 2019 Preliminary Unaudited Total Revenues of $11.9 Million,…
To view the full exhibit click
About ADMA BIOLOGICS, INC. (NASDAQ:ADMA)
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.